|
|
|
|
|
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
|
||
|
|
||
|
Cancer Pipeline • CTK110 • CTK-100144 • CTK-000147 • Discovery Compounds/10+ Targets Proteasome/CTK-100147 Project The ubiquitin-proteasome system is the major pathway for intracellular protein degradation Oncogenes of several common malignancies are regulated by this pathway. The successful introduction of Velcade™ (bortezamib) for multiple myeloma validates this therapeutic approach. Several potential natural product lead compounds have been found from Cetek’s drug discovery process, including the CTK-100147 series. These compounds are novel small molecules with highly selective, low nanomolar potency against the chymotrypsin-like activity of the proteasome. Cetek believes that this structurally distinct series of compounds have the potential for an improved safety profile. |
Cetek Corporation • 508-229-8900 • info@cetek.com Home | About Cetek
| Proprietary
Drug Discovery Technologies | Cancer Drugs & Pipeline
©1998-2006 Cetek Corporation, Marlborough, MA,
USA. |